<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045327</url>
  </required_header>
  <id_info>
    <org_study_id>PMZ-2010/CT-3.1/2018</org_study_id>
    <secondary_id>CTRI/2019/01/017196</secondary_id>
    <nct_id>NCT04045327</nct_id>
  </id_info>
  <brief_title>Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock</brief_title>
  <official_title>A Prospective, Multi-Centric, Randomized, Double-Blind, Parallel, Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock to be Used as an Adjuvant to Standard Shock Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmazz, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmazz, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-centric, randomized, double-blind, parallel, controlled
      phase-III efficacy clinical study of PMZ-2010 therapy in patients with hypovolemic shock.

      Centhaquine (previously used names, centhaquin and PMZ-2010; International Non-proprietary
      Name (INN) recently approved by WHO is centhaquine) has been found to be an effective
      resuscitative agent in rat, rabbit and swine models of hemorrhagic shock, it decreased blood
      lactate, increased mean arterial pressure, cardiac output, and decreased mortality. An
      increase in cardiac output during resuscitation is mainly attributed to an increase in stroke
      volume. Centhaquine acts on the venous α2B-adrenergic receptors and enhances venous return to
      the heart, in addition, it produces arterial dilatation by acting on central α2A-adrenergic
      receptors to reduce sympathetic activity and systemic vascular resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 105 patients will be randomized 2:1 into 2 treatment groups after meeting the
      eligibility criteria. Total 70 patients will be enrolled in PMZ-2010 group (Group 1) and in
      Normal Saline group (Group 2) total 35 patients will be enrolled.

        -  Group 1: PMZ-2010 (Dose: 0.01 mg/kg) + Standard of care

        -  Group 2: Normal Saline (Dose: Equal volume) + Standard of care In both treatment groups,
           patients will be provided the standard of care. PMZ-2010 or Normal Saline will be
           administered intravenously after randomization to hypovolemic shock patients with
           systolic arterial blood pressure ≤ 90 mmHg at presentation and continue to receive
           standard Shock Treatment. In PMZ-2010 group, dose of PMZ-2010 (0.01 mg/kg) will be
           administered as an intravenous (IV) infusion over 1 hour in 100 mL of normal saline.
           Second dose of PMZ-2010 will be administered if SBP falls below or remains below or
           equal to 90 mmHg but not before 4 hours of previous dose and total doses per day (in 24
           hours) will not exceed 3 doses. PMZ-2010 administration if needed will continue for two
           days post randomization. Minimum 1 dose or maximum 6 doses of PMZ-2010 will be
           administered within first 48 hours. post randomization. In Control group, single dose of
           equal volume of Normal Saline will be administered as intravenous (IV) infusion over 1
           hour in 100 mL of normal saline post randomization. Condition of administration will
           remain same as for PMZ-2010 group. Each patient will be monitored closely throughout
           his/her hospitalization and will be followed until discharge from randomization. Each
           patient will be assessed for efficacy parameters over 28 days from randomization to a
           clinic visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2019</start_date>
  <completion_date type="Actual">September 27, 2019</completion_date>
  <primary_completion_date type="Actual">September 23, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in systolic and diastolic blood pressure</measure>
    <time_frame>48 hours</time_frame>
    <description>Change in systolic and diastolic blood pressure - Mean through 48 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood lactate level</measure>
    <time_frame>48 hours</time_frame>
    <description>Change in blood lactate level - Mean through 48 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in base-deficit</measure>
    <time_frame>48 hours</time_frame>
    <description>Change in Base-deficit - Mean through 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Urine Output</measure>
    <time_frame>48 hours</time_frame>
    <description>Total volume of urine output - Mean through 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor(s) infused</measure>
    <time_frame>48 hours</time_frame>
    <description>Amount of total vasopressor(s) infused - Mean through 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of fluid administered</measure>
    <time_frame>48 hours</time_frame>
    <description>Total volume of fluid administered - Mean through 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doses of study drug</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of doses of study drug administered in first 48 hours post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of patients with all-cause mortality at 48 hours and 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stay in hospital, in ICU and/or on Ventilator</measure>
    <time_frame>28 days</time_frame>
    <description>Days in hospital, in ICU and/or on Ventilator - Mean through 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multiple Organ Dysfunction Syndrome Score</measure>
    <time_frame>28 days</time_frame>
    <description>Change in Multiple Organ Dysfunction Syndrome Score (MODS) - Mean through 28 days. MODS is a 5 grade scale from 0 to 4, where 0 is the best and 4 is the worst outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Acute Respiratory Distress Syndrome</measure>
    <time_frame>28 days</time_frame>
    <description>Change in Acute Respiratory Distress Syndrome (ARDS) - Mean through 28 days. ARDS will be determined using Murray Score for Acute Lung Injury which is based upon radiological findings, oxygenation status, ventilation status of the patient. A lower score of 0 is the best and about 2.5 is the worst outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glasgow coma score</measure>
    <time_frame>28 days</time_frame>
    <description>Change in Glasgow coma score (GCS) - Mean through 28 days. GCS is a 15 point scale to assess the level of consciousness of patients where less than 3 is comatose state and 15 is fully awake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>Proportion of patients with drug related adverse events during 28 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Hypovolemic Shock</condition>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypovolemic shock patients will be provided the standard of care. Following randomization 100 ml (equal volume to experimental arm) of normal saline will be administered intravenously over 1 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PMZ-2010 (centhaquine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypovolemic shock patients will be provided the standard of care. Following randomization PMZ-2010 (0.01 mg/kg) will be administered intravenously over 1 hour in 100 mL of normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline + Standard Treatment</intervention_name>
    <description>Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock</description>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Centhaquine + Standard Treatment</intervention_name>
    <description>Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock</description>
    <arm_group_label>PMZ-2010 (centhaquine)</arm_group_label>
    <other_name>PMZ-2010</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hypovolemic shock admitted to the emergency room or ICU with systolic
             blood pressure ≤ 90 mmHg at presentation and continue to receive standard shock
             treatment. Blood Lactate level indicative of hypovolemic shock (&gt;2.0 mmol/L).

        Exclusion Criteria:

          1. Development of any other terminal illness not associated with Hypovolemic shock during
             the 28-day observation period.

          2. Patient with altered consciousness not due to Hypovolemic shock.

          3. Known pregnancy.

          4. Cardiopulmonary resuscitation (CPR) before randomization.

          5. Presence of a do not resuscitate order.

          6. Patient is participating in another interventional study.

          7. Patients with systemic diseases which were already present before having trauma, such
             as: cancer, chronic renal failure, liver failure, decompensated heart failure or AIDS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Gulati, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Pharmazz, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seven Star Hospital</name>
      <address>
        <city>Nagpur</city>
        <state>Maha</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jawahar Lal Nehru Medical College &amp; Attached Hospitals</name>
      <address>
        <city>Ajmer</city>
        <zip>305001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Superspeciality Hospital</name>
      <address>
        <city>Amravati</city>
        <zip>444606</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People Tree Hospitals</name>
      <address>
        <city>Bangalore</city>
        <zip>560022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLE's Dr. Prabhakar Kore Hospital &amp; Medical Research Centre</name>
      <address>
        <city>Belgaum</city>
        <zip>590010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shri Guru Ram Rai Institute of Medical &amp; Health Sciences</name>
      <address>
        <city>Dehradun</city>
        <zip>248001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, GSVM Medical College</name>
      <address>
        <city>Kanpur</city>
        <zip>208002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Postgraduate Medical Education &amp; Research and SSKM Hospital</name>
      <address>
        <city>Kolkata</city>
        <zip>700020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George's Medical University</name>
      <address>
        <city>Lucknow</city>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College &amp; Hospital</name>
      <address>
        <city>Ludhiana</city>
        <zip>141008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidhu Hospital Pvt. Ltd.</name>
      <address>
        <city>Ludhiana</city>
        <zip>141421</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of General Medicine, JSS Hospital</name>
      <address>
        <city>Mysuru</city>
        <zip>570004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Era Hospital &amp; Research Institute</name>
      <address>
        <city>Nagpur</city>
        <zip>440008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rahate Surgical Hospital &amp; ICU</name>
      <address>
        <city>Nagpur</city>
        <zip>440008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Criticare Hospital &amp; Research Institute</name>
      <address>
        <city>Nagpur</city>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACSR Government Medical College &amp; Hospital</name>
      <address>
        <city>Nellore</city>
        <zip>524007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maulana Azad Medical College and associated Lok Nayak Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Medical Sciences, Banaras Hindu University</name>
      <address>
        <city>Varanasi</city>
        <zip>221005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Kontouli Z, Staikou C, Iacovidou N, Mamais I, Kouskouni E, Papalois A, Papapanagiotou P, Gulati A, Chalkias A, Xanthos T. Resuscitation with centhaquin and 6% hydroxyethyl starch 130/0.4 improves survival in a swine model of hemorrhagic shock: a randomized experimental study. Eur J Trauma Emerg Surg. 2019 Dec;45(6):1077-1085. doi: 10.1007/s00068-018-0980-1. Epub 2018 Jul 13.</citation>
    <PMID>30006694</PMID>
  </reference>
  <reference>
    <citation>Papalexopoulou K, Chalkias A, Pliatsika P, Papalois A, Papapanagiotou P, Papadopoulos G, Arnaoutoglou E, Petrou A, Gulati A, Xanthos T. Centhaquin Effects in a Swine Model of Ventricular Fibrillation: Centhaquin and Cardiac Arrest. Heart Lung Circ. 2017 Aug;26(8):856-863. doi: 10.1016/j.hlc.2016.11.008. Epub 2016 Dec 19.</citation>
    <PMID>28385449</PMID>
  </reference>
  <reference>
    <citation>Papapanagiotou P, Xanthos T, Gulati A, Chalkias A, Papalois A, Kontouli Z, Alegakis A, Iacovidou N. Centhaquin improves survival in a swine model of hemorrhagic shock. J Surg Res. 2016 Jan;200(1):227-35. doi: 10.1016/j.jss.2015.06.056. Epub 2015 Jun 29.</citation>
    <PMID>26216751</PMID>
  </reference>
  <reference>
    <citation>Gulati A, Zhang Z, Murphy A, Lavhale MS. Efficacy of centhaquin as a small volume resuscitative agent in severely hemorrhaged rats. Am J Emerg Med. 2013 Sep;31(9):1315-21. doi: 10.1016/j.ajem.2013.05.032. Epub 2013 Jul 19.</citation>
    <PMID>23871440</PMID>
  </reference>
  <reference>
    <citation>Lavhale MS, Havalad S, Gulati A. Resuscitative effect of centhaquin after hemorrhagic shock in rats. J Surg Res. 2013 Jan;179(1):115-24. doi: 10.1016/j.jss.2012.08.042. Epub 2012 Sep 2.</citation>
    <PMID>22964270</PMID>
  </reference>
  <reference>
    <citation>Gulati A, Lavhale MS, Garcia DJ, Havalad S. Centhaquin improves resuscitative effect of hypertonic saline in hemorrhaged rats. J Surg Res. 2012 Nov;178(1):415-23. doi: 10.1016/j.jss.2012.02.005. Epub 2012 Apr 2.</citation>
    <PMID>22487389</PMID>
  </reference>
  <results_reference>
    <citation>Anil Gulati, Dinesh Jain, Nilesh Agrawal, Prashant Rahate, Soumen Das, Rajat Chowdhuri, Deba Dhibar, Madhav Prabhu, Sameer Haveri, Rohit Agarwal, Manish Lavhale. Clinical Phase II Results Of PMZ-2010 (centhaquin) As A Resuscitative Agent For Hypovolemic Shock. Critical Care Medicine Volume 47, Issue 1, Page 12.</citation>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Plan to publish the findings after completion of the study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

